Randomized, Double-blind, Multicenter Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck who have Progressed on or after Prior Platinum-Based Chemotherapy

Trial Profile

Randomized, Double-blind, Multicenter Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck who have Progressed on or after Prior Platinum-Based Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs Pelareorep (Primary) ; Carboplatin; Paclitaxel
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Dec 2013 Planned end date changed from 1 Jan 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 20 Nov 2013 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top